Partial Seizure - Pipeline Review, H2 2015

Date: December 16, 2015
Pages: 95
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P4613E75FE5EN
Leaflet:

Download PDF Leaflet

Partial Seizure - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Partial Seizure - Pipeline Review, H2 2015’, provides an overview of the Partial Seizure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Partial Seizure
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Partial Seizure
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Partial Seizure Overview
Therapeutics Development
Pipeline Products for Partial Seizure - Overview
Partial Seizure - Therapeutics under Development by Companies
Partial Seizure - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Partial Seizure - Products under Development by Companies
Partial Seizure - Companies Involved in Therapeutics Development
Advicenne Pharma
Catalyst Pharmaceutical Partners, Inc.
Eisai Co., Ltd.
Marinus Pharmaceuticals, Inc.
Novartis AG
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
UCB S.A.
Partial Seizure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brivaracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clobazam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lacosamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levetiracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
perampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selurampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP-3089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Partial Seizure - Recent Pipeline Updates
Partial Seizure - Dormant Projects
Partial Seizure - Discontinued Products
Partial Seizure - Product Development Milestones
Featured News & Press Releases
Nov 02, 2015: Eisai Presents Results From Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan
Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting
Jan 05, 2015: Phase III Trial of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint
Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy
Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting
Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment
Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S.
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Partial Seizure, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Partial Seizure - Pipeline by Advicenne Pharma, H2 2015
Partial Seizure - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
Partial Seizure - Pipeline by Eisai Co., Ltd., H2 2015
Partial Seizure - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015
Partial Seizure - Pipeline by Novartis AG, H2 2015
Partial Seizure - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Partial Seizure - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Partial Seizure - Pipeline by UCB S.A., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Partial Seizure Therapeutics - Recent Pipeline Updates, H2 2015
Partial Seizure - Dormant Projects, H2 2015
Partial Seizure - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Partial Seizure, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

COMPANIES MENTIONED

Advicenne Pharma
Catalyst Pharmaceutical Partners, Inc.
Eisai Co., Ltd.
Marinus Pharmaceuticals, Inc.
Novartis AG
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
UCB S.A.
Skip to top


Partial Seizure - Pipeline Review, H1 2015 US$ 1,600.00 May, 2015 · 89 pages
Seizures - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 214 pages
Seizures - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 201 pages
Partial Seizure - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Partial Seizure - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: